Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23

Aimmune price target raised to $70 from $42 at Wedbush

Wedbush analyst Liana Moussatos raised her price target for Aimmune (AIMT) to $70 from $42, while reiterating an Outperform rating on the shares. Following the failure of DBV Technologies' (DBVT) Viaskin-peanut to achieve the FDA's minimum of 15% better efficacy than placebo as a minimum measure of clinical meaningfulness, the analyst anticipates FDA is likely to require another Phase 3 trial, which reduces competition risk.

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

  • 06

    Nov

AIMT Aimmune
$25.66

-0.06 (-0.23%)

03/22/17
PIPR
03/22/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees Aimmune as having regulatory advantage over DBV
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan keeps an Overweight rating on Aimmune (AIMT) with a $38 price target. While regulatory visibility will increase in the next 12 months, investors today should focus on response rates for the single highest tolerated dose, or how much peanut can an allergic person tolerate in a single exposure, Duncan tells investors in a research note. The analyst sees Aimmune's AR101 as having generated "uniquely impressive results" on the two key efficacy measures relative to DBV Technologies (DBVT), including both response rates and size of highest tolerated dose. He believes investors may be overlooking catalysts for Aimmune, including up-dosing progress from the PALISADE trial prior to Phase III results around year-end.
09/12/17
JEFF
09/12/17
NO CHANGE
Target $51
JEFF
Buy
Jefferies allergist poll shows 'meaningful upside' to DBV sales estimates
Jefferies analyst Eun Yang says her firm's poll of 33 U.S. allergists indicates "meaningful upside" to her Viaskin Peanut sales estimates in the $3.5B U.S. pediatric peanut allergy market should DBV Technologies (DBVT) win approval. The poll indicates a preference for Viaskin Peanut over Aimmune Therapeutics' (AIMT) AR101 in kids with peanut allergy given its safety profile and convenience, Yang tells investors in a research note. The analyst sees a "high likelihood" of Phase 3 success for Viaskin Peanut, which DBV is expected to announce in October. On positive data, the stock could rally up to 50% from current levels, the analyst contends. She keeps a Buy rating on DBV Technologies.
10/02/17
JMPS
10/02/17
NO CHANGE
JMPS
Outperform
Parents excited about peanut allergy immunotherapy, says JMP Securities
After surveying over 60 parents with peanut allergic children, JMP Securities analyst Liisa Bayko said she was "surprised" that 85% of respondents indicated a willingness to adopt an immunotherapy to treat the allergy. While the survey group may represent a more engaged and proactive one than the larger population, Bayko said even 30% adoption would be significant as the peanut allergy market is "enormous". The analyst, who added the survey pointed to a place for both oral and epicutaneous approaches, keeps Outperform ratings on both DBV Technologies (DBVT) and Aimmune (AIMT).
10/20/17
PIPR
10/20/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees ' increasingly favorable' risk/reward for Aimmune Phase III program
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan sees an "increasingly favorable" risk/reward for Aimmune Therapeutics' (AIMT) AR101 Phase III peanut allergy program heading into the clinical progress results in Q1 of 2018. Aimmune has a "best-in-class" approach to peanut allergy immunotherapy which can address at least 25%-40%) of the moderate to severe peanut allergic market, Duncan tells investors in a research note. The analyst believes some volatility in the shares is possible around the near-term Phase III Pepites results from "mind-share competitor" DBV Technologies (DBVT). Duncan views Aimmune as undervalued and keeps an Overweight rating on the shares with a $38 price target.
DBVT DBV Technologies
$48.07

0.92 (1.95%)

10/06/17
DBAB
10/06/17
NO CHANGE
Target $56
DBAB
Buy
DBV risk/reward favorable into Phase 3 readout, says Deutsche Bank
Deutsche Bank analyst Andrew Peters says the risk/reward for DBV Technologies, despite the stock rallying 31% year-to-date, is favorable into the Phase 3 data readout for Viaskin Peanut expected this month. The analyst continues to see a "strong rationale" for why the study should be successful. The current share value may still underappreciate the potential upside on positive data, Peters tells investors in a research note. He reiterates a Buy rating on DBV with a $56 price target.
10/12/17
SBSH
10/12/17
NO CHANGE
Target $57
SBSH
Buy
DBV news today does not impact timelines for efficacy study, says Citi
Citi analyst Liav Abraham says she confirmed with management of DBV Technologies that today's announcement regarding the Realise study has no bearing on the timelines for readout of the pivotal efficacy study for Viaksin Peanut, the Pepites study, which remains on track for a headline data readout this month. The analyst remains "constructive" on the shares ahead of the Pepites data readout in October. She notes that Realise is DBV's second Phase III study for Viaskin Peanut, and is a safety study, unlike Pepites, which is an efficacy study. Abraham has a Buy rating on DBV with a $57 price target.
10/23/17
JEFF
10/23/17
NO CHANGE
Target $37
JEFF
Buy
Jefferies still sees greater than 50% odds for DBV approval
Jefferies analyst Eun Yang believes DBV Technologies' Viaskin Peanut has greater than 50/50 odds of FDA approval even though the Phase III study missed the lower bound of proposed efficacy range. The analyst highlights the statistically significant Phase 3 data, "likely clinically meaningful tolerance" of three peanuts on Viaskin Peanut versus one peanut on placebo, and potential improved response over time. The analyst lowered her price target for DBV shares to $37 from $51 and keeps a Buy rating on the name. The stock in premarket trading is down 44% to $26.80.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

15:57
11/21/17
11/21
15:57
11/21/17
15:57
Hot Stocks
Amazon cuts prices for AWS IoT customers by 20%-40% »

Amazon said this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

T

AT&T

$34.42

-0.22 (-0.64%)

, TWX

Time Warner

$89.35

1.64 (1.87%)

15:43
11/21/17
11/21
15:43
11/21/17
15:43
Hot Stocks
Trump says AT&T, Time Warner deal not good for the country »

President Donald Trump,…

T

AT&T

$34.42

-0.22 (-0.64%)

TWX

Time Warner

$89.35

1.64 (1.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

GES

Guess

$18.11

0.33 (1.86%)

15:40
11/21/17
11/21
15:40
11/21/17
15:40
Options
Active trading in Guess ahead of earnings »

Active trading in Guess…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BZUN

Baozun

$36.16

0.66 (1.86%)

15:34
11/21/17
11/21
15:34
11/21/17
15:34
Options
Baozun options imply 15.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

OSUR

OraSure

$13.96

0.22 (1.60%)

15:32
11/21/17
11/21
15:32
11/21/17
15:32
Hot Stocks
OraSure jumps after $143M Oragene Dx devices deal »

Shares of OraSure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$102.94

0.185 (0.18%)

15:30
11/21/17
11/21
15:30
11/21/17
15:30
Periodicals
John Lasseter taking leave of absence from Pixar, notes 'missteps,' THR reports »

Disney Animation head…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTR

Dollar Tree

$97.11

2.5 (2.64%)

15:28
11/21/17
11/21
15:28
11/21/17
15:28
Recommendations
Dollar Tree analyst commentary  »

Dollar Tree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MPB

Mid Penn Bancorp

$30.37

-0.7242 (-2.33%)

15:25
11/21/17
11/21
15:25
11/21/17
15:25
Hot Stocks
Mid Penn Bancorp declares quarterly dividend of 15c per share »

Payable on January 12,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$30.37

-0.7242 (-2.33%)

15:24
11/21/17
11/21
15:24
11/21/17
15:24
Hot Stocks
Mid Penn Bancorp declares special dividend of 10c per share »

Payable on January 5,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IZEA

Izea

$4.35

-0.17 (-3.76%)

15:20
11/21/17
11/21
15:20
11/21/17
15:20
Hot Stocks
Breaking Hot Stocks news story on Izea »

Izea halted after jumping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.61

-0.41 (-0.84%)

15:20
11/21/17
11/21
15:20
11/21/17
15:20
Options
Bullish option play opened in Oracle »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IZEA

Izea

$4.35

-0.17 (-3.76%)

15:19
11/21/17
11/21
15:19
11/21/17
15:19
Hot Stocks
Izea announces signing of 'one of largest grocery chains in U.S' »

In a tweet on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.45

0.01 (0.06%)

15:19
11/21/17
11/21
15:19
11/21/17
15:19
Options
GameStop options imply 15.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ACIU

AC Immune

$10.37

-0.24 (-2.26%)

15:17
11/21/17
11/21
15:17
11/21/17
15:17
Conference/Events
AC Immune to hold a KOL luncheon meeting »

Key Opinion Leader (KOL)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
11/21/17
11/21
15:17
11/21/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/21/17
11/21
15:16
11/21/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
11/21/17
11/21
15:15
11/21/17
15:15
General news
Treasury Option Action: big buyer of put protection in the belly »

Treasury Option Action:…

UA

Under Armour

$11.47

-0.6 (-4.97%)

, UAA

Under Armour

$12.92

-0.52 (-3.87%)

15:11
11/21/17
11/21
15:11
11/21/17
15:11
Technical Analysis
Technical View: Under Armour near lows of the day, levels to watch »

The shares were last down…

UA

Under Armour

$11.47

-0.6 (-4.97%)

UAA

Under Armour

$12.92

-0.52 (-3.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.85

-0.0134 (-1.55%)

15:09
11/21/17
11/21
15:09
11/21/17
15:09
Hot Stocks
DelMar presents 'positive' interim results from VAL-083 study »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRQR

ProQR Therapeutics

15:06
11/21/17
11/21
15:06
11/21/17
15:06
Hot Stocks
ProQR Therapeutics treatment of retinitis pigmentosa granted FDA orphan status »

The FDA granted ProQR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

15:05
11/21/17
11/21
15:05
11/21/17
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

HPE

HP Enterprise

$14.16

0.065 (0.46%)

15:04
11/21/17
11/21
15:04
11/21/17
15:04
Options
Hewlett Packard Enterprise options imply 6.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

  • 11

    Dec

UA

Under Armour

$11.40

-0.675 (-5.59%)

, UAA

Under Armour

$12.88

-0.565 (-4.20%)

15:03
11/21/17
11/21
15:03
11/21/17
15:03
Periodicals
Head of footwear business leaving Under Armour, WSJ says »

Peter Ruppe, the senior…

UA

Under Armour

$11.40

-0.675 (-5.59%)

UAA

Under Armour

$12.88

-0.565 (-4.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRS

Amyris

$3.68

0.15 (4.25%)

15:01
11/21/17
11/21
15:01
11/21/17
15:01
Conference/Events
Amyris to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

TRIP

TripAdvisor

$30.48

-0.11 (-0.36%)

14:55
11/21/17
11/21
14:55
11/21/17
14:55
Periodicals
FTC investigating TripAdvisor's business practices, MJS reports »

The U.S. Federal Trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.